Cracking down on pharma delay tactics to speed generic drugs

What it does

This bill empowers the Federal Trade Commission to sue companies that file repetitive, baseless petitions to delay generic drug approvals. It defines a 'sham' petition as one that is objectively groundless and designed to obstruct a competitor's business rather than raise legitimate regulatory concerns. The FTC can impose civil penalties up to the greater of a company's drug sales revenue during the delay period or $50,000 per day per petition.

Why we flagged it

The bill's operative mechanism is to penalize frivolous petitions that delay generic drug approvals, thereby accelerating market entry of lower-cost alternatives and protecting consumer access to affordable medications.

What the text implies

• The bill creates a presumption that a series of petitions is a 'sham' if HHS determines the primary purpose was delay and refers it to the FTC, shifting burden to defendants to prove otherwise — a significant procedural advantage to the government and generic manufacturers.
• The $50,000-per-day penalty structure could impose massive liability on brand-name manufacturers (potentially millions of dollars for multi-year petition series), creating strong deterrent effect but also potential chilling of legitimate regulatory participation if the 'sham' definition is applied broadly.
• The bill excludes judicial review of HHS referrals except as a third-party Administrative Procedure Act claim by the defendant, limiting appellate oversight of the agency's delay-determination process.
• Generic manufacturers and consumers benefit indirectly through faster approvals and lower drug prices, but the bill does not explicitly authorize damages or price relief to consumers — benefits flow through market competition rather than direct compensation.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary citizens benefit from faster generic drug approvals and lower drug prices, which this bill facilitates by deterring frivolous delay tactics. The bill restricts only bad-faith litigation abuse by pharmaceutical companies, not legitimate regulatory participation or consumer rights.

Who stands to gain

• generic pharmaceutical manufacturers
• pharmacy benefit managers
• health insurers
• consumers (through lower drug prices)

Named in the bill

Federal Trade Commission, HHS / Secretary of Health and Human Services, FDA, brand-name pharmaceutical companies, generic pharmaceutical manufacturers, Federal Food, Drug, and Cosmetic Act, Clayton Act, FTC Act Section 5

Where it stands

6 cosponsors: 4 Democrats, 2 Republicans.

• Mar 24, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Mar 24, 2025 — Referred to Senate Committee on the Judiciary · Congress.gov: “Read twice and referred to the Committee on the Judiciary”
• Apr 3, 2025 — Reported out of committee · Congress.gov: “Committee on the Judiciary. Ordered to be reported without amendment favorably”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

21 lobbying clients named this bill on 31 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $30,171,567 in lobbying spend. A filing names 20 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 97% of bills with at least one filing.

Amy Klobuchar, the sponsor, reported $116,500 in PAC receipts in the 2026 cycle.

• Pharmaceutical Research and Manufacturers of America — $15,770,000 on 2 filings
• Pharmaceutical Care Management Association — $3,282,990 on 1 filing
• Blue Cross and Blue Shield Association — $2,430,000 on 2 filings
• Biotechnology Innovation Organization — $2,360,000 on 1 filing
• Kaiser Foundation Health Plan Inc — $1,420,000 on 2 filings

Lobbying Disclosure Act filings through Jul 22, 2026. A filing shows who paid to lobby on a bill it names, not what changed.